药明生物(02269.HK)合营药明海德订疫苗生产合同 总合约价值最高30亿美元
药明生物(02269.HK)公布,於上周五(14日),公司与海利生物(603718.SH)共同设立的合营企业WuXi Vaccines Ireland Limited(药明海德)与疫苗合作夥伴就疫苗产品订立总合约生产合同。
据此,药明海德须於爱尔兰建设集原液及制剂生产以及质量控制实验室於一体的综合疫苗生产基地,并为疫苗合作夥伴生产及供应若干疫苗产品,初步期限由今年2月14日起至2039年12月31日,且疫苗合作夥伴可额外续新三年,总合约价值最高达约30亿美元。预期基地将於2022年开始营运。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.